药物护理的多维框架,以提高药物坚持和患者参与度:CMO-MAPEX模型
Ramón Morillo-Verdugo1, Olatz Ibarra-Barrueta2, Maria Teresa Martin Conde3
1Pharmacy Department, Virgen de Valme University Hospital, South Seville Health District, Seville, Spain.
Patient preference and adherence
|March 5, 2026
概括
能力-动机-机会 MAPEX (CMO-MAPEX) 框架通过整合患者因素和护理背景,增强门诊医药护理中的药物坚持支持. 这种以患者为中心的方法为改善治疗管理量身定制干预措施.
科学领域:
- 医药护理 医药护理 医药护理
- 医疗保健服务研究 医疗服务研究
- 行为科学 行为科学
背景情况:
- 药物坚持对于在门诊机构有效治疗结果至关重要.
- 现有的框架往往缺乏一个多维的,以患者为中心的方法来支持坚持.
- 整合行为决定因素和患者体验对于优化药物护理至关重要.
研究的目的:
- 开发能力-动机-机会 MAPEX (CMO-MAPEX) 框架.
- 创建一个多维的,以患者为中心的,以及药物坚持支持的操作指南.
- 将坚持理论转化为门诊药物护理中的实际应用.
主要方法:
- 一个六个阶段的框架开发过程,包括叙事范围综合和专家小组审查.
- 对药物坚持的行为,经验和组织决定因素的分析.
- 整合遵守证据,治疗负担,患者体验和混合护理模型.
主要成果:
- 确定了一个三域结构 (能力,动机,机会),捕捉关键的坚持因素.
- 该框架通过评估,分层,干预和混合后续行动来运行这些领域.
- 患者报告的结果和经验措施被整合为动态的护理调整.
结论:
- CMO-MAPEX为药物坚持支持提供了一个务实的,可扩展的解决方案.
- 它将坚持理论转化为以患者为中心的药物护理.
- 该框架允许根据患者的复杂性和偏好,根据患者的复杂性和偏好,根据坚持支持进行可重复的定制.
相关概念视频
Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346
Drug Dosing: Geriatric Patients
328
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328
Oral Drug Delivery Systems: Continuous-Release Systems
104
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
104
Methods of Documentation VI: Case Management Model
992
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
992
Patient-centered Care
3.2K
Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
3.2K
Therapeutic Drug Monitoring: Affecting Factors
299
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
299

